A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.

Official Title
-----------------
A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer

Conditions
-----------------
Thyroid Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Cerenkov luminescence imaging.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant is 18 years of age or old Participant must meet one of the following: Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or [18f]-PARPi PET scan in the Nuclear Medicine Clinic Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic Exclusion Criteria: Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Thyroid cancer/nodal metastasis<br>Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area. | Diagnostic Test: Cerenkov luminescence imaging.<br>* Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80% | The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy. | Through study completion, an average of 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nodal metastases, 17-538, Memorial Sloan Kettering Cancer Center